Menu Close

Johnson & Johnson (NYSE:JNJ) Holdings Raised by Mascoma Wealth Management LLC

view original post

Mascoma Wealth Management LLC boosted its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 24.6% during the 1st quarter, Holdings Channel.com reports. The fund owned 2,321 shares of the company’s stock after purchasing an additional 458 shares during the quarter. Mascoma Wealth Management LLC’s holdings in Johnson & Johnson were worth $411,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. BlackRock Inc. increased its stake in Johnson & Johnson by 2.6% in the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock worth $34,217,654,000 after purchasing an additional 4,982,885 shares in the last quarter. State Street Corp increased its stake in Johnson & Johnson by 1.8% in the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after purchasing an additional 2,492,359 shares in the last quarter. Geode Capital Management LLC increased its stake in Johnson & Johnson by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock worth $7,576,867,000 after purchasing an additional 1,084,834 shares in the last quarter. Norges Bank purchased a new position in Johnson & Johnson during the 4th quarter valued at about $4,172,929,000. Finally, Legal & General Group Plc grew its stake in Johnson & Johnson by 5.8% during the 4th quarter. Legal & General Group Plc now owns 17,420,146 shares of the company’s stock valued at $2,980,062,000 after acquiring an additional 948,306 shares in the last quarter. Hedge funds and other institutional investors own 68.78% of the company’s stock.

JNJ has been the topic of several research analyst reports. The Goldman Sachs Group lifted their target price on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Credit Suisse Group lifted their target price on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Daiwa Capital Markets assumed coverage on Johnson & Johnson in a research note on Wednesday, June 22nd. They set an “outperform” rating on the stock. Finally, Citigroup lowered their price target on Johnson & Johnson from $210.00 to $205.00 in a research note on Tuesday, May 17th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $191.29.

JNJ opened at $175.44 on Thursday. The business has a 50 day moving average price of $176.74 and a 200 day moving average price of $174.23. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. The firm has a market cap of $461.65 billion, a P/E ratio of 23.64, a price-to-earnings-growth ratio of 3.53 and a beta of 0.63.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, topping the consensus estimate of $2.60 by $0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The firm had revenue of $23.43 billion during the quarter, compared to analyst estimates of $23.62 billion. During the same period in the previous year, the company earned $2.59 EPS. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. As a group, analysts anticipate that Johnson & Johnson will post 10.23 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were issued a $1.13 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 annualized dividend and a yield of 2.58%. The ex-dividend date of this dividend was Monday, May 23rd. Johnson & Johnson’s payout ratio is 60.92%.

In other news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,785,140. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 78,161 shares of company stock valued at $13,895,302. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.